Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01710722 · ClinicalTrials.gov registry record · NA

The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man

A NA study, sponsored by Pennington Biomedical Research Center.

Completed
Registry status
NA
Development phase
45
Enrollment target

NCT01710722 is a NA study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 45 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01710722, a NA study, has completed, sponsored by Pennington Biomedical Research Center.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target

Study Summary

The purpose of this study is to compare three treatments to see which causes the most weight loss, fat loss, loss of stomach fat and improvement in blood tests like cholesterol.

Interventions

  • DRUG caffeine and ephedrine
  • DRUG Leptin A
  • DRUG caffeine, ephedrine, and leptin A

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2001-02
Est. Completion 2002-02
Phase NA

What the Registry Record Tells You About NCT01710722

The ClinicalTrials.gov registry entry for NCT01710722 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which caffeine and ephedrine is the first listed.

NCT01710722 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01710722 about?

NCT01710722 is a clinical study titled "The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man". The purpose of this study is to compare three treatments to see which causes the most weight loss, fat loss, loss of stomach fat and improvement in blood tests like cholesterol.

What is the current status of trial NCT01710722?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2001-02. Estimated completion is 2002-02.

What interventions are being tested in trial NCT01710722?

The interventions under investigation include: caffeine and ephedrine (DRUG), Leptin A (DRUG), caffeine, ephedrine, and leptin A (DRUG).

Who is sponsoring clinical trial NCT01710722?

This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.